LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) — Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone dipropionate lotion USP (augmented), 0.05%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility.
According to IQVIA, U.S. sales of betamethasone dipropionate lotion (augmented), 0.05% were approximately $10 million for the twelve months ended August 2019.
Bay Street News